Barry L Stoddard

US Patent:

20060293505, Dec 28, 2006

Filed:

Jan 19, 2006

Appl. No.:

11/336487

Inventors:

Barry Stoddard - Bellevue WA, US
Kathleen Pratt - Seattle WA, US
Kazuo Fujikawa - Seattle WA, US
Earl Davie - Bellevue WA, US

International Classification:

C07K 14/745
G06F 19/00

US Classification:

530383000, 702019000

Abstract:

A detailed three-dimensional structure for the C-terminal C2 domain of blood coagulation factor VIII is disclosed. The novel truncated factor VIII constructs which were designed so as to omit a significant portion of the flexible full length protein are also part of the present invention. In addition, the crystals of the protein, both in the presence and absence of bound ligands are also included. Furthermore, methods of identifying antagonists of the human factor VIII protein which can be used to inhibit coagulation or to stabilize and activate factor VIII mutants are also disclosed. Furthermore, methods of identifying variations of the C2 domain sequence and structure that can be incorporated into intact factor VIII for the purpose Of administration to hemophiliac patients who are immunoreactive against wild type factor VIII are disclosed.

US Patent:

20110294217, Dec 1, 2011

Filed:

Feb 12, 2010

Appl. No.:

13/201442

Inventors:

Audrey McConnell-Smith - San Diego CA, US
Barry L. Stoddard - Bellevue WA, US

Assignee:

FRED HUTCHINSON CANCER RESEARCH CENTER - Seattle WA

International Classification:

C12N 9/16
C12N 15/63
C07H 21/04

US Classification:

435440, 435196, 536 232, 4353201

Abstract:

An engineered highly specific DNA-cleavage enzyme delivers a site-specific nick in a double stranded DNA, to cleave one DNA strand within its target site while leaving the opposing DNA strand intact. The engineered enzyme provides the ability to induce a gene conversion event in a mammalian cell. An engineered sequence-specific nickase derived from a LAGLIDADG homing endonuclease is altered by a single amino acid residue, wherein the amino acid residue is involved in the polarization of solvent molecules and acid-base catalysis in the active site without affecting direct contacts between the enzyme and either the bound DNA or bound metal ions. Engineered, site-specific nickase variants, such as of I-AniI and other homing endonucleases, are particularly useful in targeted genome engineering as well as therapeutic, targeted gene repair.

US Patent:

20140068817, Mar 6, 2014

Filed:

Mar 5, 2012

Appl. No.:

14/002823

Inventors:

Stefan Dittmar - Noblesville IN, US
George Singletary - Ankeny IA, US
Asha Palta - Carmel IN, US
Barry Stoddard - Bellevue WA, US
Paul Olivier - Seattle WA, US

Assignee:

Targeted Growth, Inc. - Seattle WA

International Classification:

C12N 15/82

US Classification:

800290, 4353201, 800298, 800312, 800306, 800314, 8003174, 800322, 8003201, 8003202, 8003203, 800320, 435419, 800313

Abstract:

The present invention provides expression vectors comprising polynucleotides encoding chimeric sucrose isomerases, and methods of using the same. In addition, transgenic plants expressing said chimeric sucrose isomerases are provided. Furthermore, methods of increasing average seed weight, seed number and/or seed size of a plant by using said chimeric sucrose isomerases are provided.

US Patent:

20210388119, Dec 16, 2021

Filed:

Jun 28, 2021

Appl. No.:

17/361087

Inventors:

- Seattle WA, US
Barry L. Stoddard - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

C07K 19/00
C12N 15/62
C07K 14/00
C07K 14/44
C07K 7/08
C07K 14/47
C07K 14/55

Abstract:

Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.

US Patent:

20200190220, Jun 18, 2020

Filed:

Feb 26, 2020

Appl. No.:

16/802377

Inventors:

- Seattle WA, US
Barry L. Stoddard - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

C07K 19/00
C07K 14/44
C07K 14/00
C12N 15/62
C07K 14/55
C07K 14/47
C07K 7/08

Abstract:

Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.

US Patent:

20190002590, Jan 3, 2019

Filed:

Dec 2, 2016

Appl. No.:

15/780397

Inventors:

- Seattle WA, US
Barry L. Stoddard - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

C07K 19/00
C07K 14/55
C07K 14/47
C07K 14/00
C07K 7/08

Abstract:

Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.

US Patent:

20170298329, Oct 19, 2017

Filed:

Mar 16, 2017

Appl. No.:

15/461091

Inventors:

- Seattle WA, US
Mark T Groudine - Seattle WA, US
Barry L. Stoddard - Seattle WA, US
Michael A Bender - Seattle WA, US

International Classification:

C12N 9/22

Abstract:

Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human β-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more γ-globin gene promoter(s) to achieve increased expression of a γ-globin gene; (f) to mutate one or more δ-globin gene promoter(s) to achieve increased expression of a δ-globin gene; and/or (g) to correct one or more β-globin gene mutation(s).

US Patent:

20150166969, Jun 18, 2015

Filed:

Feb 22, 2013

Appl. No.:

14/380935

Inventors:

- Seattle WA, US
Mark T Groudine - Seattle WA, US
Barry L. Stoddard - Seattle WA, US
Michael A Bender - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

C12N 9/16

Abstract:

Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) ad/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human β-globin locus; (d) to disrupt a HbP silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbP silencing region; (e) to mutate one or more γ-globin gene promoter(s) to achieve increased expression of a γ-globin gene; (f) to mutate one or more δ-globin gene promoter(s) to achieve increased expression of a δ-globin gene; and/or (g) to correct one or more β-globin gene mutation(s).

Author:

Barry L. Stoddard

ISBN #:

3540251065